The effectiveness of the Hungarian-developed candidate drug has been confirmed by numerous studies conducted on various human cancer cell lines, and animal experiments on hormone-independent aggressive breast cancer models also clearly demonstrate its exceptional efficacy.

Sadly, the OECD’s latest report revealed that we lost 328 per 100,000 of our countrymen to the deadly disease, the most in the European Union. The reasons are multifold.